Developer docs
API playgroundTry for free, no card

Search company profiles

Terapet

Full company profile

uuid0002iol

Namestring
Terapet
Legal namestring
Terapet
Websiteurl
terapet.ch
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Terapet is a Geneva-based Swiss Medtech company spun out of CERN, founded in 2019, that develops and manufactures nuclear imaging systems for radiation oncology. The company's technology focuses on real-time, in-vivo dose verification and monitoring during cancer treatment, with a primary application in proton therapy where precise dose delivery is critical to treatment efficacy and patient safety.

Terapet's product portfolio comprises two distinct offerings. Qualγscan is the company's first commercial product, a nuclear imaging device designed for real-time dose monitoring during cancer treatment and for validation of radiation doses delivered to patients; it is positioned as Terapet's anchor commercial offering with regulatory clearance pathway for the healthcare sector. TheraVivo is an in-development in-vivo proton therapy dose verification project funded in part by a Eurostars grant, extending the platform toward next-generation particle therapy imaging workflows. Underlying both is proprietary nuclear imaging technology leveraging the founders' CERN physics lineage.

The company sells to cancer treatment centers and hospitals running proton therapy programs, addressing pain points around treatment accuracy verification and reduction of side effects from radiation mis-dosing. Terapet is privately held and venture-backed, having raised a cumulative disclosed total of approximately $14.9 million across nine funding events between 2019 and 2026 from venture investors (EFI Lake Geneva Ventures, Nina Capital, FONGIT, Venture Kick) and non-dilutive Swiss deep-tech grants (Innosuisse, Eurostars). The organization operates with 11–50 employees and is headquartered in Geneva, Switzerland; revenue and pricing are not publicly disclosed.

Short descriptiontext

Terapet is a Geneva-based CERN spin-off Medtech company that develops and manufactures nuclear imaging systems for real-time dose verification and monitoring during proton therapy and other cancer treatments, serving hospitals and cancer treatment centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMeyrin, Switzerland
HQ citystring
Meyrin
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
nuclear medical imaging, proton therapy monitoring, radiation dose verification, particle therapy systems, cancer treatment imaging
Industry2 codes
PRIMARYHLAHABAH
Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAKAFAC
Radiation Oncology
NAICS code3 codes
  • Irradiation Apparatus Manufacturing334517
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code3 codes
  • X-Ray Apparatus & Tubes & Related Irradiation Apparatus3844
  • Laboratory Analytical Instruments3826
  • Industrial Instruments For Measurement, Display, And Control3823
Product category
Medical Imaging Equipment
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Qualγscan
Description

First commercialized nuclear imaging product by Terapet for quality gamma scanning applications.

startupticker.ch
+1 more record
Core offering1 text field

Terapet develops and manufactures nuclear imaging systems used for real-time dose monitoring during cancer treatment. Its first commercial product, Qualγscan, provides quality gamma scanning to validate and monitor radiation doses delivered during particle therapy. The TheraVivo project extends this capability to in-vivo proton therapy dose verification, targeting precision oncology workflows at clinical sites.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Terapet is a Swiss Medtech company offering nuclear imaging products for radiation therapy applications. The company has a portfolio consisting of its first commercial product, Qualγscan, which provides real-time dose monitoring during cancer treatment, and an emerging product development project called TheraVivo focused on in-vivo proton therapy dose verification. The two products address different aspects of nuclear imaging in cancer treatment—Qualγscan is the currently commercialized offering while TheraVivo represents next-generation technology for proton therapy verification.

Product and service2 records
1Qualγscan
CategoryNuclear medical imaging device
Description

Nuclear imaging system designed for real-time dose monitoring during cancer treatment. It enables quality gamma scanning to validate and monitor radiation doses delivered to patients during particle therapy, and is intended for cancer treatment centers and hospitals.

2TheraVivo
CategoryProton therapy dose verification
Description

In-vivo proton therapy dose verification technology developed to provide real-time, in-vivo monitoring of radiation dose delivery during proton therapy. It is targeted at clinical oncology settings using particle therapy.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major medical imaging and diagnostics OEM including nuclear medicine (SPECT/PET) and oncology solutions. Broadly comparable as a large incumbent with overlapping clinical buyer relationships and the capacity to enter adjacent niches like proton therapy verification.

TypeDirect peer
Description

Provides patient QA and dosimetry solutions for radiation therapy including proton therapy. Closely comparable to Terapet as both deliver quality assurance and dose verification hardware/software for radiation oncology workflows.

TypeDirect peer
Description

US-based manufacturer of radiation therapy QA and dosimetry instruments used in proton and photon therapy centers. Direct comparable given overlapping product categories (detectors, phantoms, QA software) serving the same clinical end users.

TypeDirect peer
Description

German specialist in radiation dosimetry and detector technology for medical physics. Comparable because PTW supplies the detectors, phantoms, and QA systems used alongside proton therapy delivery — directly adjacent to Terapet's nuclear imaging platform.

TypeBroad incumbent
Description

Global medical imaging OEM with SPECT/CT, PET/CT, and radiation oncology offerings. Relevant as a potential competitor and as the dominant installed base of nuclear imaging systems that Terapet would either complement or displace.

TypeDirect peer
Description

Canadian manufacturer of QA phantoms, software, and dose verification tools for radiation therapy. Closely comparable to Terapet at the radiation therapy QA product level, serving the same hospital medical physics teams.

TypeEmerging player
Description

US-based compact proton therapy system manufacturer. Comparable as a focused player in proton therapy delivery; overlaps with Terapet at the clinical buyer level (proton centers) but does not address dose verification imaging.

TypeBroad incumbent
Description

Global health technology company with diagnostic imaging, image-guided therapy, and oncology portfolios. Comparable as a broad incumbent whose radiation oncology and nuclear medicine footprint overlaps with Terapet's clinical target market.

9IBA (Ion Beam Applications)
TypeDirect peer
Description

Belgian leader in proton therapy systems and radioisotopes. IBA is directly comparable because it both supplies proton therapy equipment and offers dosimetry/QA solutions, operating in the same clinical workflow that Terapet addresses.

TypeDirect peer
Description

Hungarian manufacturer of SPECT, PET, and hybrid nuclear imaging systems for preclinical and clinical use. Comparable as a specialized nuclear imaging hardware vendor serving research and clinical nuclear medicine buyers that overlap with Terapet's customer profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Terapet

Medical Imaging Equipmentterapet.ch

Terapet is a Geneva-based CERN spin-off Medtech company that develops and manufactures nuclear imaging systems for real-time dose verification and monitoring during proton therapy and other cancer treatments, serving hospitals and cancer treatment centers.

What Terapet does

Terapet is a Geneva-based Swiss Medtech company spun out of CERN, founded in 2019, that develops and manufactures nuclear imaging systems for radiation oncology. The company's technology focuses on real-time, in-vivo dose verification and monitoring during cancer treatment, with a primary application in proton therapy where precise dose delivery is critical to treatment efficacy and patient safety.

Terapet's product portfolio comprises two distinct offerings. Qualγscan is the company's first commercial product, a nuclear imaging device designed for real-time dose monitoring during cancer treatment and for validation of radiation doses delivered to patients; it is positioned as Terapet's anchor commercial offering with regulatory clearance pathway for the healthcare sector. TheraVivo is an in-development in-vivo proton therapy dose verification project funded in part by a Eurostars grant, extending the platform toward next-generation particle therapy imaging workflows. Underlying both is proprietary nuclear imaging technology leveraging the founders' CERN physics lineage.

The company sells to cancer treatment centers and hospitals running proton therapy programs, addressing pain points around treatment accuracy verification and reduction of side effects from radiation mis-dosing. Terapet is privately held and venture-backed, having raised a cumulative disclosed total of approximately $14.9 million across nine funding events between 2019 and 2026 from venture investors (EFI Lake Geneva Ventures, Nina Capital, FONGIT, Venture Kick) and non-dilutive Swiss deep-tech grants (Innosuisse, Eurostars). The organization operates with 11–50 employees and is headquartered in Geneva, Switzerland; revenue and pricing are not publicly disclosed.

Terapet firmographics

Firmographics
Name
Terapet
Legal name
Terapet
Website
https://terapet.ch
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Terapet is a Geneva-based CERN spin-off Medtech company that develops and manufactures nuclear imaging systems for real-time dose verification and monitoring during proton therapy and other cancer treatments, serving hospitals and cancer treatment centers.
Ownership category
akta.pro rank

Terapet industry classification

Industry
Product category
Medical Imaging Equipment
NAICS
Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Laboratory Analytical Instruments (3826), Industrial Instruments For Measurement, Display, And Control (3823)
akta.pro industry
PRIMARYHLAHABAH
Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAKAFAC
Radiation Oncology

Keywords

  • Nuclear medical imaging
  • Proton therapy monitoring
  • Radiation dose verification
  • Particle therapy systems
  • Cancer treatment imaging

Where Terapet is headquartered

Location

Headquarters

HQ city
Meyrin
HQ country
Switzerland
HQ region
Europe

Markets served

Terapet business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Terapet product offering

Product offering

Core offering

Terapet develops and manufactures nuclear imaging systems used for real-time dose monitoring during cancer treatment. Its first commercial product, Qualγscan, provides quality gamma scanning to validate and monitor radiation doses delivered during particle therapy. The TheraVivo project extends this capability to in-vivo proton therapy dose verification, targeting precision oncology workflows at clinical sites.

Product overview

Terapet is a Swiss Medtech company offering nuclear imaging products for radiation therapy applications. The company has a portfolio consisting of its first commercial product, Qualγscan, which provides real-time dose monitoring during cancer treatment, and an emerging product development project called TheraVivo focused on in-vivo proton therapy dose verification. The two products address different aspects of nuclear imaging in cancer treatment—Qualγscan is the currently commercialized offering while TheraVivo represents next-generation technology for proton therapy verification.

Differentiator

Problem solved

Functional benefit

Brands

  • Qualγscan: First commercialized nuclear imaging product by Terapet for quality gamma scanning applications.
  • TheraVivo

Products and services

  • Qualγscan Nuclear imaging system designed for real-time dose monitoring during cancer treatment. It enables quality gamma scanning to validate and monitor radiation doses delivered to patients during particle therapy, and is intended for cancer treatment centers and hospitals.
  • TheraVivo In-vivo proton therapy dose verification technology developed to provide real-time, in-vivo monitoring of radiation dose delivery during proton therapy. It is targeted at clinical oncology settings using particle therapy.

Companies that use Terapet

Customer profile

Segments1 record

Ideal customer profiles1 record

Terapet technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Terapet partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Terapet competitors and assessment

Company assessment

Broad incumbents

  • GE HealthCare: Major medical imaging and diagnostics OEM including nuclear medicine (SPECT/PET) and oncology solutions. Broadly comparable as a large incumbent with overlapping clinical buyer relationships and the capacity to enter adjacent niches like proton therapy verification.
  • Siemens Healthineers: Global medical imaging OEM with SPECT/CT, PET/CT, and radiation oncology offerings. Relevant as a potential competitor and as the dominant installed base of nuclear imaging systems that Terapet would either complement or displace.
  • Philips Healthcare: Global health technology company with diagnostic imaging, image-guided therapy, and oncology portfolios. Comparable as a broad incumbent whose radiation oncology and nuclear medicine footprint overlaps with Terapet's clinical target market.

Direct peers

  • Sun Nuclear (Mirion Medical): Provides patient QA and dosimetry solutions for radiation therapy including proton therapy. Closely comparable to Terapet as both deliver quality assurance and dose verification hardware/software for radiation oncology workflows.
  • Standard Imaging: US-based manufacturer of radiation therapy QA and dosimetry instruments used in proton and photon therapy centers. Direct comparable given overlapping product categories (detectors, phantoms, QA software) serving the same clinical end users.
  • PTW Freiburg: German specialist in radiation dosimetry and detector technology for medical physics. Comparable because PTW supplies the detectors, phantoms, and QA systems used alongside proton therapy delivery — directly adjacent to Terapet's nuclear imaging platform.
  • Modus Medical Devices: Canadian manufacturer of QA phantoms, software, and dose verification tools for radiation therapy. Closely comparable to Terapet at the radiation therapy QA product level, serving the same hospital medical physics teams.
  • IBA (Ion Beam Applications): Belgian leader in proton therapy systems and radioisotopes. IBA is directly comparable because it both supplies proton therapy equipment and offers dosimetry/QA solutions, operating in the same clinical workflow that Terapet addresses.
  • Mediso Medical Imaging Systems: Hungarian manufacturer of SPECT, PET, and hybrid nuclear imaging systems for preclinical and clinical use. Comparable as a specialized nuclear imaging hardware vendor serving research and clinical nuclear medicine buyers that overlap with Terapet's customer profile.

Emerging players

  • Mevion Medical Systems: US-based compact proton therapy system manufacturer. Comparable as a focused player in proton therapy delivery; overlaps with Terapet at the clinical buyer level (proton centers) but does not address dose verification imaging.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Terapet social profiles

Digital presence

Terapet financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Terapet leadership team

Management profile

Number of profiles

Profiles3 records

Terapet funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Terapet M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Terapet

What does Terapet do?

Terapet develops and manufactures nuclear imaging systems used for real-time dose monitoring during cancer treatment. Its first commercial product, Qualγscan, provides quality gamma scanning to validate and monitor radiation doses delivered during particle therapy. The TheraVivo project extends this capability to in-vivo proton therapy dose verification, targeting precision oncology workflows at clinical sites.

Is Terapet a public or private company?

Terapet is a private company. It is classified as venture growth investor backed and is currently operating.

When was Terapet founded?

Terapet was founded in 2019. It employs 11 to 50 people.

Where is Terapet based?

Terapet is headquartered in Meyrin, Switzerland, in the Europe region.

Who are Terapet's main competitors?

Broad incumbents on record are GE HealthCare, Siemens Healthineers and Philips Healthcare. Direct peers are Sun Nuclear (Mirion Medical), Standard Imaging, PTW Freiburg, Modus Medical Devices, IBA (Ion Beam Applications) and Mediso Medical Imaging Systems. Mevion Medical Systems is listed as an emerging player.

Does Terapet have an API?

No public API is recorded for Terapet.

What industry is Terapet in?

Terapet's product category is Medical Imaging Equipment. Its primary akta.pro industry code is HLAHABAH, Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim), with a secondary code of HLAKAFAC, Radiation Oncology. Its NAICS code is 334517 and its SIC code is 3844.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
startupticker.chLarge grants back four Swiss deep tech startupsFour Swiss startups—Metafuels, Terapet, Avientus, and DeltaSpark—have secured grant funding totalling approximately CHF 5 million across cleantech, medtech, and autonomous logistics sectors. Metafuels received EUR 1.92 million from the Netherlands Enterprise Agency to develop a first commercial synthetic aviation fuel facility at the Port of Rotterdam using its aerobrew methanol-to-jet technology, while Terapet secured a Eurostars grant including EUR 772,000 for its TheraVivo project focused on in-vivo proton therapy dose verification. Avientus obtained CHF 300,000 through the SPRIN-D Challenge for autonomous drone development, and DeltaSpark received support from the Migros Pioneer Fund for its electrochemical carbon-capture technology that converts industrial CO2 into mineral products for construction.startupticker.chEuropean funds to propel Swiss projectsFour Swiss startups—EH Group, reCIRCLE, Vandria, and Terapet—have received European grants to advance their innovative projects in energy, sustainability, biotech, and medical imaging. The funding supports collaborative R&D efforts under EU programs like Horizon Europe and Eurostars, aiming to develop clean fuel technologies, reusable packaging solutions, new drug candidates, and diagnostic devices.VenturelabCollaborative success: Terapet's partnership with Yonsei University and Oncosoft Inc. secures multi-million funding from Innosuisse and KIATTerapet, in partnership with Yonsei University and Oncosoft Inc., secured multi-million funding from Innosuisse and KIAT to develop a personalized quality assurance device for Heavy Ion Therapy. The collaboration, officially launching on November 1st, 2023, aims to pioneer patient-specific quality assurance at South Korea's first carbon ion therapy center. This initiative is part of a bilateral innovation program between Switzerland and South Korea to promote knowledge exchange and business development.Greater Geneva Bern area (GGBa)Terapet raises CHF 2.3 million for its next-generation cancer treatment technologyGeneva-based medtech company Terapet has closed its first Pre-Series A investment round, raising CHF 2.3 million to support the marketing and sales of its proton therapy quality assurance device, Qualγscan. The funding was co-led by EFI Lake Geneva Ventures and Nina Capital, with participation from existing shareholders including Fongit and Venturekick. New board members Giovanni Leo and Sebastian Anastassiou have joined to support the company's development of next-generation nuclear imaging products.startupticker.chCHF 2.3M to market Terapet first product and boost R&DSwiss MedTech company Terapet secured CHF 2.3 million in Pre-Series A funding led by EFI Lake Geneva Ventures and Nina Capital to commercialize its first product, Qualγscan, and expand R&D. The investment enables the marketing of this proton therapy quality assurance device and supports the development of future nuclear imaging technologies in collaboration with CERN and Politecnico di Milano.startupticker.chFIF funding supports three women led deeptech startupsThe Fondation Genevoise pour l’Innovation Technologique awarded FIF funding to three women-led deeptech startups: iOnctura, EBAMed, and Terapet. iOnctura received a record CHF 400,000 growth loan, while EBAMed and Terapet each secured CHF 100,000 seed loans to support their medical technology innovations.startupticker.chCHF1.5 million for making proton therapy safer and fasterTerapet received about CHF1.53 million in non-dilutive funding to develop a full-scale proton therapy prototype. The funds support two consortia with CERN and Karolinska Institute, starting 1 February 2021 for three years. The collaborations aim to make proton therapy safer, more precise, and faster.startupticker.chOne million Swiss francs for TerapetTerapet SA raised one million Swiss francs in an oversubscribed seed round from EFI, Nina Capital, FSI, and three angel investors. The funds will develop its first full-scale prototype with CERN support and prepare for clinical validation at The Skandion Clinic in Sweden. The device aims to enable real-time, in-vivo monitoring of proton doses during cancer treatment.startupticker.chBIC of CERN selects Arc Power and Terapet as new incubateesArc Power and Terapet each received a CHF 50,000 grant from the Swiss BIC of CERN Technologies for a two-year entrepreneurship program. Arc Power develops radiation-resistant electronics for space, while Terapet's PET scanner improves proton therapy precision. The winners also gain access to CERN and PSI intellectual property and support.